The Independents read some recent viewer questions, comments an criticisms.
Hedgeye CEO Keith McCullough and Altaira Senior Managing Director Ralph Acampora discuss their outlooks for the economy and markets.
FBN’s Liz MacDonald on the latest developments from Merck and NewLink’s Ebola vaccine tests.
Canaccord Genuity U.S. Portfolio Strategy Tony Dwyer and Merk Investments President Axel Merk discuss their outlook for the ECB.
What do the results of the midterm elections mean for freedom?
The Hollywood and Vine panel weighs in on Taylor Swift, Bill Cosby, Johnny Depp’s speech at the Hollywood Film Awards and Bono’s bike accident.
FBN’s Charles Payne, NewOak Capital President James Frischling, small business expert Susan Solovic, retail analyst Hitha Prabhakar and Penn Financial Group founder Matt McCall on the outlook for Cubist Pharmaceuticals.
FBN’s Ashley Webster breaks down the details of Pfizer’s cancer drug deal with Merck .
Fort Pitt Capital Group V.P. Kim Forrest, Athena Advisor Services Senior V.P. Dan Stecich and FBN’s Cheryl Casone on Apple’s milestone, UPS’s new business plan and top stocks.
Hailo Founder Jay Bregman and Nylon Media CEO Paul Greenberg discusses rapid growth overseas and his decision to stop doing business in the U.S.
Adviser Investment Management Chief Investment Strategist Jim Lowell, A&G Capital CIO Hilary Kramer and Trading Advantage Senior Market Strategist Scott Bauer on the outlook for the markets and where the opportunities are for investors.
BNP Paribas North America CEO Jean-Yves Fillion weighs in on the economy and how clients are benefitting from a low-rate environment.
Wearables.com CEO Luis Rincon on the retailers that have shut down access to Apple Pay.
FBN’s Charles Payne, NewOak Capital President James Frischling, Sterne Agee Chief Economist Lindsey Piegza, FNC contributor Jonathan Hoenig, retail analyst Hitha Herzog and Penn Financial Group founder Matt McCall review some of the show’s stock picks.
Athena Capital Advisors CEO and Founder Lisette Cooper on the U.S. and global markets, oil prices and the Fed.
NYU School of Medicine’s Dr. Devi Nampiaparampil discusses the effectiveness of Merck ’s new cancer drug.
Merck CEO Kenneth Frazier discusses the motivation behind the $8.4 billion deal to buy Cubist, and the drugmaker’s strategy to constantly look for value-creating opportunities.
Rich Jeanneret of EY Transaction Advisory Services says cash and confidence are behind strong deal making.
John Spallanzani GFI Group gives his outlook for year-end cash flow and explains why Jamie Dimon is his pick for business person of the year.
FBN’s Ashley Webster breaks down the details of Merck ’s acquisition of Cubist Pharmaceuticals.